{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:19Z","timestamp":1791920899247,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clml.2017.12.008","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T13:34:48Z","timestamp":1514986488000},"page":"e143-e146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-2853","authenticated-orcid":false,"given":"Elaine","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9203","authenticated-orcid":false,"given":"Gustavo","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Chiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelash","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Mbue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvari V.","family":"Yellapragada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.12.008_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.008_bib2","first-page":"1","article-title":"Human immunodeficiency viruses and human T-cell lymphotropic viruses","volume":"67","year":"1996","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.clml.2017.12.008_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/QAD.0000000000000986","article-title":"Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy","volume":"30","author":"Olszewski","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2017.12.008_bib4","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hernandez-Ramirez","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clml.2017.12.008_bib5","first-page":"e2009032","article-title":"EBV and HIV-related lymphoma","volume":"1","author":"Bibas","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2017.12.008_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/PNVQ0PQGXHVY6L7G","article-title":"HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases","volume":"121","author":"Thompson","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2017.12.008_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2017.12.008_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.008_bib9","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.12.008_bib10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.12.008_bib11","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.12.008_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.12.008_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.008_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2017.12.008_bib15","first-page":"237","article-title":"HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: implications for HIV persistence","volume":"1","author":"Maldarelli","year":"2015","journal-title":"J\u00a0Virus Erad"},{"key":"10.1016\/j.clml.2017.12.008_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","article-title":"Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy","volume":"5","author":"Sandoval-Sus","year":"2017","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017315483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017315483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:09Z","timestamp":1761870609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017315483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2152265017315483"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}